false
English
Catalog
2021 World Conference on Lung Cancer (Posters)
FP09. Mobocertinib (TAK-788) in EGFR Exon 20 Inser ...
FP09. Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes From EXCLAIM Extension Cohort
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Dr. Rosario Aljera-Campelo presented the data on patient-reported outcomes from the Sritan extension core phase 1-2 study of Moxeritinib in previously treated patients with EFR-XON20 insertion positive metastatic non-small cell lung cancer. The study included 96 patients, and Moxeritinib showed statistically significant and clinically meaningful improvements in lung cancer symptoms such as dyspnea, cough, and chest pain. Global health status was maintained or improved in most patients, and general health-related quality of life remained stable throughout treatment. Adverse events such as diarrhea, dry skin, rash, and decreased appetite were reported, but did not significantly impact quality of life. Overall, Moxeritinib showed promise in improving patient outcomes in this difficult-to-treat population.
Asset Subtitle
Maria Rosario García Campelo
Meta Tag
Speaker
Maria Rosario García Campelo
Topic
Novel Therapeutics and Targeted Therapies
Keywords
Dr. Rosario Aljera-Campelo
patient-reported outcomes
Sritan extension core phase 1-2 study
Moxeritinib
metastatic non-small cell lung cancer
×
Please select your language
1
English
5
普通话
11
Dutch